FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC - Trial NCT06403111
Access comprehensive clinical trial information for NCT06403111 through Pure Global AI's free database. This Phase 2 trial is sponsored by Changzhou No.2 People's Hospital and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 62 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
Interventional
combination product
Sponsor & Location
Changzhou No.2 People's Hospital
Timeline & Enrollment
Phase 2
Jun 01, 2024
Jun 01, 2026
Primary Outcome
12-Months Progression-Free Survival Rate (12month-PFS)
Summary
This study plans to reconstruct intestinal microecology through fecal microbiota
 transplantation (FMT), and combine first-line standard therapy to enhance the anti-tumor
 immune effect at the same time, thereby extending the progression-free survival of patients
 and improving the prognosis of patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06403111
Non-Device Trial